Tracy Staton

Biography for Tracy Staton

Tracy Staton, Senior Editor

Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at tracy@fiercemarkets.com or find her on LinkedIn.

Articles by Tracy Staton

Showdown time for Amgen, Sandoz, with Neupogen biosim hearing set March 2

Novartis and its Neupogen biosimilar are steamrolling toward the U.S. market. But Amgen hasn't given up stopping the product in its tracks. The biotech last week urged a California court to block the biosimilar launch, with FDA approval expected as soon as March 9.

FDA to pharma: Scrap that fine-print risk info in DTC ads

Look for some big changes next time you run across a magazine ad for Crestor or Viagra or any of the brands on heavy rotation. The FDA has decided that its long-standing disclose-all policy on side effects was wrong. Way wrong.

UPDATED: Novo Nordisk joins pharma's IPO clique with plans for tech subsidiary spinoff

Novo Nordisk has joined the spinoff club. The Danish drugmaker says it's ready to let its information technology unit, NNIT, go solo via an initial public offering.

Look for a new Sanofi CEO by March, says chairman, as earnings top forecast

Striking out in our CEO search? Not us, says Sanofi. Chairman Serge Weinberg says the board is talking to a "limited number of candidates" and expects to make a choice very soon. A choice, by the way, from outside Sanofi, Weinberg says.

Pfizer grabs Hospira's biosims, generic injectables in $15B takeover

Pfizer has snapped up Hospira, an injectables specialist, for $90 per share, or some $15 billion, plus debt assumption.

Merck finally rolls out sleep aid Belsomra after FDA roadblocks

Merck's long-awaited insomnia drug Belsomra (suvorexant) has now hit pharmacy shelves in the U.S. The drug is a first-in-class sleep aid finally approved last year after an initial rejection by the FDA.

Moody's: Big Pharmas face growing patent-loss threats, but some pipelines are improving

For the past couple of years, the pharma industry has had something of a reprieve from patent-cliff nightmares. But according to Moody's Investors Service, some companies face new threats to their sweet dreams.

It's put up or shut up time for Sanofi and MannKind as Afrezza hits the market

Sanofi and MannKind heralded the launch of Afrezza today, as their inhaled insulin hit store shelves in the U.S. For MannKind, it's a vindication after years of development setbacks. For Sanofi, it's a chance to show that it can broaden its base of diabetes sales beyond the hypersuccessful Lantus.

Big Pharma farms out safety monitoring to $2B-and-growing industry

Big Pharma has been hiring out all sorts of functions companies once did in-house: sales, manufacturing, and IT services, to name a few. But according to The Wall Street Journal, one of the fastest-growing fields for pharma contractors isn't any of these. It's drug safety.

J&J lawyers aim to discredit ex-FDA chief in Risperdal breast-development case

Johnson & Johnson has fired back against former FDA chief David Kessler, who testified against the company last week in a Risperdal liability case. Kessler can't be trusted on drug safety, J&J's lawyers said, because he's a "hired gun" known for attacking drugmakers in court.